Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1

被引：1

作者：

Locke, Frederick L. ^{[1
]}

Ghobadi, Armin ^{[2
]}

Lekakis, Lazaros J. ^{[3
]}

Miklos, David B. ^{[4
]}

Jacobson, Caron A. ^{[5
]}

Jacobsen, Eric ^{[5
]}

Braunschweig, Ira ^{[6
]}

Oluwole, Olalekan O. ^{[7
]}

Siddiqi, Tanya ^{[8
]}

Lin, Yi ^{[9
]}

Reagan, Patrick M. ^{[10
]}

Farooq, Umar ^{[11
]}

Deol, Abhinav ^{[12
]}

Bot, Adrian ^{[13
]}

Rossi, John M. ^{[13
]}

Jiang, Yizhou ^{[13
]}

Xue, Allen ^{[13
]}

Go, William Y. ^{[13
]}

Neelapu, Sattva S. ^{[14
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Univ Miami Hlth Syst, Sylvester Comprehens Care Ctr, Miami, FL USA

[4] Stanford Univ, Stanford, CA 94305 USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

[7] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Rochester, Sch Med, Rochester, NY USA

[11] Univ Iowa, Iowa City, IA USA

[12] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA

[13] Kite, Santa Monica, CA USA

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷

关键词：

CAR T cell therapy; large B cell lymphoma;

D O I：

10.1016/j.clml.2018.07.203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

NHL-102

引用

页码：S276 / S276

页数：1

共 50 条

[21] A Comparison of 2-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel; Axi-Cel) and SCHOLAR-1 in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL)
Neelapu, Sattva S.
Locke, Frederick L.
Bartlett, Nancy L.
Lekakis, Lazaros J.
Reagan, Patrick
Miklos, David B.
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Crump, Michael
Kuruvilla, John
Van den Neste, Erin
Farooq, Umar
Navale, Lynn
DePuy, Venita
Kim, Jenny
Gisselbrecht, Christian
MOLECULAR THERAPY, 2020, 28 (04) : 575 - 576
[22] Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1
Rossi, John M.
Galon, Jerome
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Go, William Y.
Bot, Adrian
CANCER RESEARCH, 2018, 78 (13)
[23] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Ghobadi, Armin
Jacobson, Caron A.
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick J.
Flinn, Ian W.
Farooq, Umar
Goy, Andre
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Xue, Allen
Jiang, Yizhou
Bot, Adrian
Rossi, John M.
Kim, Jenny J.
Go, William Y.
Locke, Frederick L.
BLOOD, 2018, 132
[24] ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma
Oluwole, Olalekan O.
Kenderian, Saad S.
Shiraz, Parveen
Karmali, Reem
Reshef, Ran
McCarthy, Philip L.
Ghosh, Nilanjan
Lazaryan, Aleksandr
Filosto, Simone
Poddar, Soumya
Mao, Daqin
Peng, Andrew
Kilcoyne, Adrian
Nahas, Myrna
Neelapu, Sattva S.
BLOOD, 2022, 140 : 10318 - 10320
[25] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Ghobadi, Armin
Jacobson, Caron A.
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick
Flinn, Ian W.
Farooq, Umar
Goy, Andre
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Xue, Allen
Jiang, Yizhou
Bot, Adrian
Rossi, John M.
Kim, Jenny J.
Go, William Y.
Locke, Frederick L.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[26] 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Zhang, Muchen
Fang, Ying
Xu, Pengpeng
Cheng, Shu
Wang, Li
Zhao, Wei-Li
BLOOD, 2018, 132
[27] Axicabtagene Ciloleucel (Axi-cel) in Patients With Refractory Large B Cell Lymphoma (NHL): Long-term Follow-up of ZUMA-1
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D. B.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O. O.
Siddiqi, T.
Lin, Y.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J. M.
Navale, L.
Jiang, Y.
Aycock, J. S.
Elias, M.
Wiezorek, J. S.
Go, W.
Neelapu, S. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 25 - 25
[28] ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel in Patients With Relapsed or Refractory Large B-Cell Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 13 - 14
[29] Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Pinnix, Chelsea C.
Gunther, Jillian R.
Dabaja, Bouthaina S.
Strati, Paolo
Fang, Penny
Hawkins, Misha C.
Adkins, Sherry
Westin, Jason
Ahmed, Sairah
Fayad, Luis
Lee, Hun Ju
Nair, Ranjit
Steiner, Raphael E.
Iyer, Swaminathan P.
Rodriguez, M. Alma
Wang, Michael
Flowers, Christopher
Neelapu, Sattva S.
Nastoupil, Loretta J.
BLOOD ADVANCES, 2020, 4 (13) : 2871 - 2883
[30] Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
Neelapu, Sattva S.
Jacobson, Caron A.
Ghobadi, Armin
Miklos, David B.
Lekakis, Lazaros J.
Oluwole, Olalekan O.
Lin, Yi
Braunschweig, Ira
Hill, Brian T.
Timmerman, John M.
Deol, Abhinav
Reagan, Patrick M.
Stiff, Patrick
Flinn, Ian W.
Farooq, Umar
Goy, Andre H.
McSweeney, Peter A.
Munoz, Javier
Siddiqi, Tanya
Chavez, Julio C.
Herrera, Alex F.
Bartlett, Nancy L.
Bot, Adrian A.
Shen, Rhine R.
Dong, Jinghui
Singh, Kanwarjit
Miao, Harry
Kim, Jenny J.
Zheng, Yan
Locke, Frederick L.
BLOOD, 2023, 141 (19) : 2307 - 2315

← 1 2 3 4 5 →